AptarGroup, Inc. (ATR) Sees Pharma Segment Momentum Driving Record Earnings Growth

In this article, we will be taking a look at the 13 Most Oversold Healthcare Stocks So Far in 2025. AptarGroup, Inc. is amongst them.

AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery and consumer product dosing technologies, highlighted its growth strategy and long-term outlook during its Investor Day on September 9, 2025. Executive presentations emphasized strong momentum in the Pharma segment, driven by rising demand for innovative biologics, injectables, and patient-friendly drug delivery solutions.

In Q2 2025, AptarGroup, Inc. (NYSE:ATR) reported a 6% increase in revenue compared to the prior year, with net income rising 24% to $112 million and adjusted EBITDA up 13%. Earnings per share grew 25%, reflecting operational efficiencies and strong demand across the Pharma and Closures segments.

 AptarGroup, Inc. (ATR) Sees Pharma Segment Momentum Driving Record Earnings Growth

The company signaled confidence in its sustained performance by announcing a nearly 7% increase in its quarterly dividend to $0.48 per share, marking 32 consecutive years of dividend growth. AptarGroup, Inc. (NYSE:ATR) also returned $100 million to shareholders in dividends and share repurchases during the second quarter, totaling $210 million for the first half of the year, demonstrating a shareholder-friendly capital allocation approach.

While we acknowledge the risk and potential of ATR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ATR and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy NOW 

Disclosure: None.